EGFR and non-small cell lung carcinoma: Furthermore, this review did not include the emerging evidence regarding gefitinib resistance in NSCLC and additional novel therapeutic options that are currently being developed to mitigate such chemotherapeutic resistance issues within clinical cases of EGFR mutation-positive NSCLC, including the possible deployment of long non-coding ribonucleic acid (RNA) and microRNA molecular players to carry out such chemoresistance mitigation effector functions [27-29].